logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Cbmg Holdings Completes $120 Million In Series A Funding, Accelerating Development Of Car-T Therapy Pipelines And R&D For Innovative Solid Tumor Therapies

Cbmg Holdings Completes $120 Million In Series A Funding, Accelerating Development Of Car-T Therapy Pipelines And R&D For Innovative Solid Tumor Therapies

09/30/21, 8:35 AM
Money raised
$120 million
Round Type
series a
CBMG Holdings (or the "Company"), a Cayman Island biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer and degenerative diseases, today announced the closing of a $120 million Series A investment, led by AstraZeneca-CICC Fund, Sequoia Capital China and Yunfeng Capital. Both new and certain existing investors, including GIC and TF Capital, subscribed to the Series A financing.

Company Info

Company
Cbmg Holdings
Additional Info
CBMG Holdings develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company operates a state-of-the-art facility in Rockville, Maryland with five GMP rooms in order to augment its global research and development capabilities and to support clinical development of multiple cell therapy platform technologies in the United States. The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. The Company currently conducts ongoing studies in China, for CAR-T therapies targeting blood cancers, including C-CAR039, an anti-CD19, CD20 BiCAR treatment for non-Hodgkin lymphoma (NHL), in addition to T cell receptor (TCR-T) and tumor-infiltrating lymphocytes (TIL) therapies targeting solid tumors. The China NMPA (formerly CFDA) approved the Company's IND application for a Phase II trial for AlloJoin®, its "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA) and has accepted the Company's IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.